Development of prophylactic vaccines for genital and neonatal herpes.
Over five decades numerous conventional candidate live attenuated and killed vaccines have failed to prevent genital herpes in clinical trials. However, a vaccine consisting of recombinant glycoprotein D from herpes simplex virus (HSV)-2 and deacylated monophosphoryl lipid A adjuvant has recently shown partial efficacy against clinical disease transmitted from HSV-1 and -2 seronegative women (73-74%). Comparisons between the efficacy of this vaccine and previous failed candidates and their effects on the immune system should help guide development of better vaccines through selection of appropriate HSV proteins, adjuvants or cytokines and newer vaccine vectors, such as DNA vaccines, recombinant viral vaccines and specific HSV mutants.
Jones
Cheryl A
CA
Herpesvirus Research Unit, & Department of Immunology and Infectious Diseases, The Children's Hospital at Westmead, Westmead, Australia.
Cunningham
Anthony L
AL
D002986:Clinical Trials as Topic; D005260:Female; D006558:Herpes Genitalis / Q000276:immunology / Q000517:prevention & control* / Q000635:transmission; D006561:Herpes Simplex / Q000276:immunology / Q000517:prevention & control* / Q000635:transmission; D018259:Herpesvirus 1, Human / Q000235:genetics / Q000276:immunology*; D018258:Herpesvirus 2, Human / Q000235:genetics / Q000276:immunology*; D006801:Humans; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000517:prevention & control* / Q000821:virology; D019444:Vaccines, DNA; D022223:Vaccines, Subunit; D014765:Viral Vaccines / Q000008:administration & dosage / Q000276:immunology*; D014779:Virus Replication / Q000235:genetics
D019444:Vaccines, DNA; D022223:Vaccines, Subunit; D014765:Viral Vaccines